IL153328A0 - 2-aminothiazoline derivatives and their use as no-synthase inhibitors - Google Patents

2-aminothiazoline derivatives and their use as no-synthase inhibitors

Info

Publication number
IL153328A0
IL153328A0 IL15332801A IL15332801A IL153328A0 IL 153328 A0 IL153328 A0 IL 153328A0 IL 15332801 A IL15332801 A IL 15332801A IL 15332801 A IL15332801 A IL 15332801A IL 153328 A0 IL153328 A0 IL 153328A0
Authority
IL
Israel
Prior art keywords
synthase inhibitors
aminothiazoline
derivatives
aminothiazoline derivatives
synthase
Prior art date
Application number
IL15332801A
Original Assignee
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc
Publication of IL153328A0 publication Critical patent/IL153328A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/18—Nitrogen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL15332801A 2000-06-09 2001-06-07 2-aminothiazoline derivatives and their use as no-synthase inhibitors IL153328A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0007397A FR2810037B1 (en) 2000-06-09 2000-06-09 USE OF 2-AMINOTHIAZOLINE DERIVATIVES AS INDUCTIBLE NO-SYNTHASE INHIBITORS
PCT/FR2001/001760 WO2001094325A1 (en) 2000-06-09 2001-06-07 2-aminothiazoline derivatives and their use as no-synthase inhibitors

Publications (1)

Publication Number Publication Date
IL153328A0 true IL153328A0 (en) 2003-07-06

Family

ID=8851134

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15332801A IL153328A0 (en) 2000-06-09 2001-06-07 2-aminothiazoline derivatives and their use as no-synthase inhibitors

Country Status (29)

Country Link
EP (1) EP1299365B1 (en)
JP (1) JP4238026B2 (en)
KR (1) KR20030025931A (en)
CN (1) CN1202096C (en)
AP (1) AP2002002708A0 (en)
AR (1) AR029937A1 (en)
AT (1) ATE305460T1 (en)
AU (1) AU2001266124A1 (en)
BR (1) BR0111986A (en)
CA (1) CA2411760C (en)
DE (1) DE60113689T2 (en)
DK (1) DK1299365T3 (en)
DZ (1) DZ3367A1 (en)
EA (1) EA200300010A1 (en)
EC (1) ECSP024375A (en)
ES (1) ES2248347T3 (en)
FR (1) FR2810037B1 (en)
HK (1) HK1057900A1 (en)
HR (1) HRP20020970A2 (en)
HU (1) HUP0301000A2 (en)
IL (1) IL153328A0 (en)
MA (1) MA25814A1 (en)
MX (1) MXPA02012071A (en)
NO (1) NO20025884L (en)
NZ (1) NZ522968A (en)
OA (1) OA12286A (en)
PL (1) PL360285A1 (en)
WO (1) WO2001094325A1 (en)
ZA (1) ZA200209769B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1430019B1 (en) * 2001-09-26 2009-12-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Sphingolipids
JP4365681B2 (en) * 2001-11-09 2009-11-18 アベンティス・ファーマ・ソシエテ・アノニム 2-Amino-4-heteroarylethyl-thiazoline derivatives and their use as inhibitors of inducible NO synthase
DE60234117D1 (en) * 2001-11-09 2009-12-03 Aventis Pharma Sa 2-AMINO-4-PYRIDYLMETHYL-THIAZOLINE DERIVATIVES AND THEIR USE AS INDUCIBLE NO-SYNTHASE INHIBITORS
ES2256583T3 (en) * 2001-11-09 2006-07-16 Aventis Pharma S.A. DERIVATIVES OF 2-AMINO-TIAZOLINE AND ITS USE AS INHIBITORS OF THE INDUCIBLE NON-SYNTHEASE.
AU2002238889A1 (en) * 2002-03-14 2003-09-22 Dainippon Pharmaceutical Co., Ltd. Nitrogen monoxide synthase inhibitors
DK1539724T3 (en) * 2002-08-07 2008-02-11 Neuraxon Inc Aminobenzothiazole compounds with NOS inhibitory activity
DE10332560B4 (en) * 2003-07-11 2010-07-08 Chiracon Gmbh Process for the preparation of β-heteroaryl-2-alanine compounds via 2-amino-2- (heteroarylmethyl) -carboxylic acid compounds
KR101800507B1 (en) 2015-09-18 2018-01-18 주식회사 이엔이티아이 How to take advantage of the purification plants equipment and self-cleaning screen to clean up pollution by continue flowing sewage and process wastewater into the river

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066662A (en) * 1990-05-21 1991-11-19 Warner-Lambert Company Substituted oxazolidin-2-ones and 1,2,4-oxadiazolin-5-ones and derivatives thereof acting at muscarinic receptors
WO1994012165A2 (en) * 1992-11-27 1994-06-09 The Wellcome Foundation Limited Enzyme inhibitors
CN1077886C (en) * 1993-10-21 2002-01-16 G·D·瑟尔公司 Amidino derivatives useful as nitric oxide synthase inhibitors
AU4149696A (en) * 1994-11-15 1996-06-06 Merck & Co., Inc. Substituted heterocycles as inhibitors of nitric oxide synthase
WO2001047931A1 (en) * 1999-12-24 2001-07-05 Kyowa Hakko Kogyo Co., Ltd. Fused purine derivatives

Also Published As

Publication number Publication date
NO20025884D0 (en) 2002-12-06
ATE305460T1 (en) 2005-10-15
JP2003535853A (en) 2003-12-02
DE60113689T2 (en) 2006-07-13
DZ3367A1 (en) 2001-12-13
CA2411760C (en) 2009-12-29
NO20025884L (en) 2003-01-29
JP4238026B2 (en) 2009-03-11
HUP0301000A2 (en) 2003-08-28
PL360285A1 (en) 2004-09-06
ES2248347T3 (en) 2006-03-16
KR20030025931A (en) 2003-03-29
CA2411760A1 (en) 2001-12-13
ECSP024375A (en) 2003-02-06
AU2001266124A1 (en) 2001-12-17
ZA200209769B (en) 2004-03-02
FR2810037B1 (en) 2004-04-23
CN1202096C (en) 2005-05-18
HRP20020970A2 (en) 2005-02-28
EP1299365B1 (en) 2005-09-28
AR029937A1 (en) 2003-07-23
OA12286A (en) 2006-05-12
EP1299365A1 (en) 2003-04-09
DE60113689D1 (en) 2006-02-09
WO2001094325A1 (en) 2001-12-13
DK1299365T3 (en) 2006-02-06
EA200300010A1 (en) 2003-06-26
CN1444572A (en) 2003-09-24
NZ522968A (en) 2005-07-29
HK1057900A1 (en) 2004-04-23
FR2810037A1 (en) 2001-12-14
MXPA02012071A (en) 2004-09-10
MA25814A1 (en) 2003-07-01
AP2002002708A0 (en) 2002-12-31
BR0111986A (en) 2003-04-01

Similar Documents

Publication Publication Date Title
AU7392101A (en) 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors
HK1053124A1 (en) Substituted quinazoline derivatives and their use as inhibitors
SI1686119T1 (en) Pyrimidine-5-one derivatives as LDL-PLA2 inhibitors
HK1057214A1 (en) New mandelic acid derivatives and their use as throbin inhibitors
HK1061854A1 (en) Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
GB0025782D0 (en) Use of inhibitors
AU2001244355A1 (en) Heterobiarylsulphonamides and their use as pde 7 inhibitors
HUP0203961A3 (en) 3-phenoxy-1-phenyl acetylene derivatives and their use as herbicedes
IL151614A0 (en) Apomorphine derivatives and methods for their use
PL349769A1 (en) New amidinobenzylamine derivatives and their use as thrombin inhibitors
AU5693101A (en) New thiochromane derivatives and their use as thrombin inhibitors
PL361733A1 (en) Sulfamidothienopyrimidines and the use of the same as phosphodiesterase v inhibitors
AU2001276027A1 (en) Heteroaryl-beta-alanine derivatives as alpha 4 integrin inhibitors
HRP20020970A2 (en) 2-aminothiazoline derivatives and their use as no-synthase inhibitors
PL359668A1 (en) Biphenyl derivatives and the use thereof as integrin inhibitors
SI1259515T1 (en) Thienopyridine derivatives and their use as anti-inflammatory agents
SI1146041T1 (en) Derivatives of heterocycloalkylbenzocyclobutane and heteroarylbenzocyclobutane and their use as inhibitors of the recapture of serotonine and of noradrenaline
HK1053059A1 (en) New use of imidazotriazinon derivatives
IL153327A0 (en) 4,5-dihydro-thiazo-2-ylamine derivatives and their use as no-synthase inhibitors
AU2001266123A1 (en) 4,5-dihydro-thiazo-2-ylamine derivatives and their use as no-synthase inhibitors
AU8973201A (en) Biphenyl derivatives and the use thereof as integrin inhibitors
SI1268480T1 (en) 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors
PL340617A1 (en) Derivatives of 2-acylpyridine
SI1150996T1 (en) New amidinobenzylamine derivatives and their use as thrombin inhibitors
AU2002223649A1 (en) Vegh inhibitors and their use